Acquisition

October 01, 2026 The Manager Listing Department, The National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 Dear Sir/ Madam, Trading Symbol: ZOTA Sub: Intimation of Acquisition of 39,228 equity shares of M/s Davaindia Health Mart Limited, Wholly Owned Subsidiary of the Company, by way of subscription to the right issue Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 With reference to the captioned subject, we, M/s Zota Health Care Limited (the “Company”) would like to inform you that the Company has acquired 39,228 equity shares of M/s Davaindia Health Mart Limited, Wholly Owned Subsidiary (“WOS”) of the Company, by way of subscription to the right issue. The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are annexed herewith as Annexure-1. This is for your information and record. Thanking you, Yours faithfully, For Zota Health Care Limited Ashvin Variya (Group Company Secretary & Compliance Officer) Place: Surat Encl.: a/a Registered Office: Zota House, 2/896, Hira Modi Street, Sagrampura, Surat-395002 Ph: +91 261 2331601 Email: info@zotahealthcare.com Web: www.zotahealthcare.com CIN: L24231GJ2000PLC038352 Annexure-1 Particulars Details Name of the target entity, details in brief i. Name of the Target Entity: Davaindia Health such as size, turnover etc. Mart Limited ii. Business of the Target Entity: To operate retail Generic Pharmacy chain under Company Owned Company Operated (COCO) model of Davaindia Generic Pharmacy. iii. Financial details: As per the audited financial statements for the Financial Year 2025-26, the turnover of WOS was Rs. 267.71 crores. At present, the total paid-up share capital is Rs. 298.13 lakhs. Whether the acquisition would fall within No, the acquisition does not fall within the ambit of related party transaction(s) and whether related party transactions. The promoter/ promoter the promoter/ promoter group/ group group/ group companies do not have any interest in companies have any interest in the entity WOS and the said transaction is done at arm’s length being acquired? If yes, nature of interest basis. and details thereof and whether the same is done at “arm’s length” Industry to which the entity being acquired Pharmaceutical belongs Objects and effects of acquisition The Company has made further investment in WOS (including but not limited to, disclosure of as a part of strategic investment and to mitigate reasons for acquisition of target entity, if working capital requirements of WOS. Post to this its business is outside the main line of acquisition, M/s Davaindia Health Mart Limited business of the listed entity); continues to remain as the WOS of the Company. Brief details of any governmental or N.A. regulatory approvals required for the acquisition Indicative time period for completion of On October 01, 2026, the Company has acquired the the acquisition said 39,228 equity shares of WOS by subscription to the right issue. Nature of consideration - whether cash Cash consideration by way of acquisition of Equity consideration or share swap and details of Shares. the same; Cost of acquisition or the price at which Cost of acquisition for subscription of 39,228 Equity the shares are acquired Shares offered on right basis is Rs. 5075.00/- per equity share (including premium of Rs. 5065.00/- per equity share) aggregating to Rs. 19,90,82,100.00/-. Percentage of shareholding / control The Company has further acquired 39,228 equity acquired and / or number of shares shares of WOS. Post to this acquisition, the M/s acquired Davaindia Health Mart Limited continues to remain as the WOS of the Company. Brief background about the entity M/s Davaindia Health Mart Limited was incorporated acquired in terms of products/line of on January 01, 2020, domiciled in India; operating business acquired, date of incorporation, COCO stores of Davaindia Generic Pharmacy having history of last 3 years turnover, country in store presence in 23 states and 5 Union Territories which the acquired entity has presence with 1855 stores as on June 30, 2026 and offering and any other significant information (in 2000+ SKUs inclusive of Medicines, Ayurvedic, brief) Cosmetics, Nutraceutical and OTC products. During last three financial years the details of turnover of WOS were as follows: FY 2025-26 Rs. 267.71 crores FY 2024-25 Rs. 109.93 crores FY 2023-24 Rs. 44.77 crores